• BI partners with Tsinghua for immuno therapies biospectrumasia
    September 06, 2018
    This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders (RBB) and Cancer Immunology and Immune Modulation Research Departments.
PharmaSources Customer Service